FDA removes hold on clinical trial for phase 2,3 for COVAXIN-BBV152 says Ocugen
May 23, 2022
Malvern (Pennsylvania) [US], May 23 : Biotechnology company Ocugen on Monday announced that the US Food and Drug Administration (FDA) lifted the clinical hold on the Company's Phase 2, 3 clinical trials for COVAXIN™ (BBV152).
Chairman, CEO, and Co-Founder of Ocugen Inc., Dr Shankar Musunuri said, "We're extremely pleased that we can proceed with our clinical trials for COVAXIN, our whole virus inactivated COVID-19 vaccine candidate. The need for delivering an additional, differentiated vaccine option, we believe, remains a priority."
Dr Musunuri thanked the clinical trial partners and site collaborators for their ongoing support.
"Ocugen will now work with study sites to fully resume this clinical development program immediately," he added.
He told that COVAXIN™ (BBVI52) is an investigational vaccine candidate product in the US. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), National Institute of Virology (NIV), reported the Globe News Wire.
The vaccine is a highly purified and inactivated vaccine that is manufactured using a Vero cell manufacturing platform, he said.
Adding on, Dr Musunuri said that with more than 350 million doses having been administered to adults outside the US, COVAXIN is currently approved for adults in India and authorized for emergency use in 25 countries.
Applications for emergency use authorization are pending in more than 60 other countries.
The vaccine is listed by the World Health Organization (WHO) as authorized for emergency use. And, as many as 110 countries have agreed to mutual recognition of COVID-19 vaccination certificates with India that includes vaccination using COVAXIN. The trade name, COVAXIN, has not been evaluated by the FDA, reported the Globe News Wire.
The biotechnology company, Ocugen is focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines that improve health and offer hope for people and global communities, he told.
Dr Munusuri said, "We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs."
